<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01647932</url>
  </required_header>
  <id_info>
    <org_study_id>SEMI-IC-CLOR</org_study_id>
    <nct_id>NCT01647932</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure</brief_title>
  <acronym>CLOROTIC</acronym>
  <official_title>Safety and Efficacy of the Combination of Loop Diuretics With Thiazide-type Diuretics in Patients With Decompensated Heart Failure: a Double-blind, Randomized, Placebo-controlled Trial (CLOROTIC Trial).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Society of Internal Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Society of Internal Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a combined diuretic therapy (loop diuretics
      with thiazide-type diuretics) is more effective (in terms of improving fluid overload
      symptoms) among patients with decompensated heart failure in comparison with loop diuretic
      alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Volume overload is an important clinical target in heart failure management, typically
      addressed using loop diuretics. An important and challenging subset of heart failure patients
      exhibit fluid overload despite significant doses of loop diuretics. One approach to overcome
      loop diuretic resistance is the addition of a thiazide-type diuretic to produce diuretic
      synergy via &quot;sequential nephron blockade,&quot; first described more than 40 years ago. Although
      potentially able to induce diuresis in patients otherwise resistant to high doses of loop
      diuretics, this strategy has not been subjected to large-scale clinical trials to establish
      safety and clinical efficacy. Combination diuretic therapy using any of several thiazide-type
      diuretics can more than double daily urine sodium excretion to induce weight loss and edema
      resolution. To our knowledge there are no clinical trials designed to prove the efficacy and
      safety of combined diuretic therapy (a commonly used therapy) among patients with
      decompensated heart failure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in body weight</measure>
    <time_frame>Bodyweight will be measured every 24 hours (during hospitalisation) from the date of inclusion / randomisation until the date of discharge.</time_frame>
    <description>Bodyweight will be measured every 24 hours (during hospitalisation) from the date of inclusion / randomisation until the date of discharge.
Changes in body weight measurements: the mean of weight lost every 24 hours and the total weight lost from baseline to the 5th day of hospitalisation.
Participants will be followed for the duration of hospital stay, an expected average of 9 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported dyspnea</measure>
    <time_frame>Patient-reported dyspnea is assessed every 24 hours (during hospitalisation) from the date of inclusion / randomisation until the date of discharge.</time_frame>
    <description>Patient-reported dyspnea is assessed every 24 hours (during hospitalisation) from the date of inclusion / randomisation until the date of discharge.
Patient-reported dyspnea is assessed with the use of a visual-analogue scale (VAS) and the Linker 7 point scale.
Changes in patient-reported dyspnea: changes in the dyspnea scales from baseline to the 5th day of hospitalisation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diuresis</measure>
    <time_frame>24-hour diuresis will be quantified every 24 hours (during hospitalisation) from the 1st day until the 4th day of hospitalisation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening renal function</measure>
    <time_frame>Renal function will be determined every 24 hours (during hospitalisation) from the date of inclusion / randomisation until the date of discharge.</time_frame>
    <description>Renal function will be determined every 24 hours (during hospitalisation) from the date of inclusion / randomisation until the date of discharge.
Renal function is assessed with the serum creatinine level. Worsening renal function is defined as an increase in the serum creatinine level of more than 0.3 mg/dl at any time during hospitalisation Participants will be followed for the duration of hospital stay, an expected average of 9 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in electrolyte levels (sodium and potassium)</measure>
    <time_frame>Electrolyte levels (sodium and potassium) will be determined every 24 hours (during hospitalisation) from the date of inclusion / randomisation until the date of discharge.</time_frame>
    <description>Electrolyte levels (sodium and potassium) will be determined every 24 hours (during hospitalisation) from the date of inclusion / randomisation until the date of discharge.
Electrolyte levels are assessed with the serum sodium and potassium levels. Participants will be followed for the duration of hospital stay, an expected average of 9 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metrics of diuretic response</measure>
    <time_frame>weight loss and net fluid loss per mg of furosemide</time_frame>
    <description>weight loss and net fluid loss per mg of furosemide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (all-cause and heart failure)</measure>
    <time_frame>Mortality (all-cause and heart failure) at 30 and 90days post-discharge</time_frame>
    <description>Mortality (all-cause and heart failure) at 30 and 90days post-discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization (all-cause and heart failure)</measure>
    <time_frame>Rehospitalization (all-cause and heart failure) at 30 and 90days post-discharge</time_frame>
    <description>Rehospitalization (all-cause and heart failure) at 30 and 90days post-discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Loop plus thiazide-type diuretic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loop diuretic plus hydrochlorothiazide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loop diuretic plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Loop diuretic plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrochlorothiazide</intervention_name>
    <description>hydrochlorothiazide according to clearance of creatinine; &gt;50ml/min 25mg daily, 20-50ml/min 50mg daily amd &lt;20ml/min 100mg daily.</description>
    <arm_group_label>Loop plus thiazide-type diuretic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo according to clearance of creatinine; &gt;50ml/min 1/2 pill daily, 20-50ml/min 1 pill daily amd &lt;20ml/min 2 pills daily.</description>
    <arm_group_label>Loop diuretic plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of chronic heart failure

          -  Admission for acute decompensated heart failure

          -  There is no prespecified inclusion criterion with respect to heart failure etiology
             and/or ejection fraction

          -  Receipt of an oral loop diuretic for at least 1 month before hospitalization, at a
             dose between 80 mg and 240 mg daily in the case of furosemide and an equivalent dose
             in the case of a different loop diuretic (20 mg of torasemide or 1 mg of bumetanide
             was considered to be equivalent to 40 mg of furosemide)

        Exclusion Criteria:

          -  Other etiologies of fluid overload different from heart failure

          -  Hyponatremia: any symptomatic sodium value or a sodium level below 125mmol/l

          -  Unstable patients: acute coronary syndrome, cardiogenic shock or ICU admission.

          -  Patients requiring inotropic agents or renal replacement therapies

          -  Life expectancy &lt; 6 months

          -  Prior treatment with thiazide-type diuretics

          -  Aldosterone antagonists are permitted if the patient had been taking them on a
             long-term basis (at least 30 days before randomisation)

          -  Pregnancy or breastfeeding period

          -  Active alcoholism and/or other substance abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Carles Trullas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Failure Study Group, Spanish Society of Internal Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joan Carles Trullas, MD, PhD</last_name>
    <phone>0034+667509933</phone>
    <email>jctv5153@comg.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesc Formiga, MD, PhD</last_name>
    <phone>0034+650964944</phone>
    <email>fformiga@bellvitgehospital.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Internal Medicine Service, Hospital d'Olot (Girona)</name>
      <address>
        <city>Olot</city>
        <state>Girona</state>
        <zip>17800</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Carles Trullas, MD, PhD</last_name>
      <phone>0034+66750933</phone>
      <email>jctv5153@comg.cat</email>
    </contact>
    <investigator>
      <last_name>Joan Carles Trullas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010 Nov 2;56(19):1527-34. doi: 10.1016/j.jacc.2010.06.034. Review.</citation>
    <PMID>21029871</PMID>
  </reference>
  <reference>
    <citation>ter Maaten JM, Valente MA, Damman K, Hillege HL, Navis G, Voors AA. Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy. Nat Rev Cardiol. 2015 Mar;12(3):184-92. doi: 10.1038/nrcardio.2014.215. Epub 2015 Jan 6. Review.</citation>
    <PMID>25560378</PMID>
  </reference>
  <reference>
    <citation>Trullàs JC, Morales-Rull JL, Casado J, Freitas Ramírez A, Manzano L, Formiga F; CLOROTIC investigators. Rationale and Design of the &quot;Safety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure (CLOROTIC) Trial:&quot; A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Effect of Combined Diuretic Therapy (Loop Diuretics With Thiazide-Type Diuretics) Among Patients With Decompensated Heart Failure. J Card Fail. 2016 Jul;22(7):529-36. doi: 10.1016/j.cardfail.2015.11.003. Epub 2015 Nov 11.</citation>
    <PMID>26576715</PMID>
  </reference>
  <reference>
    <citation>Trullàs JC, Morales-Rull JL, Formiga F. [Diuretic therapy in acute heart failure]. Med Clin (Barc). 2014 Mar;142 Suppl 1:36-41. doi: 10.1016/S0025-7753(14)70081-8. Review. Spanish.</citation>
    <PMID>24930082</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spanish Society of Internal Medicine</investigator_affiliation>
    <investigator_full_name>Joan Carles Trullas Vila</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Diuretics</keyword>
  <keyword>Diuretic resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

